GLP-1semaglutideobesitydenmarkprescribingpharmacoepidemiology

Danish study of 189,392 semaglutide starters finds concomitant prescriptions fall

Antiasthmatic, analgesic and antidepressant prescribing dropped below projected trends 12 months after initiation, while anxiolytic use rose 16% and stayed elevated at two years.

By Maren Holt · Senior Reporter, GLP-1

Oct 24 20:00 ETSource: Diabetes, obesity & metabolism

The wire

01An interrupted time series in Diabetes, Obesity & Metabolism tracked 189,392 adults starting semaglutide for weight management in Denmark from December 2022 to December 2024, finding antiasthmatic prescriptions at 12 months 18% below projection and analgesics and antidepressants each 7% below.
02Prescribers managing obesity-related comorbidities may need to plan for deprescribing reviews, while the rise in anxiolytic use (RR 1.16) warrants monitoring during therapy.
03The design is observational and registry-based; glucose-lowering declines were mirrored in a negative control cohort, and the authors do not establish causation.

From the source

Impact of Semaglutide Introduction on the Use of Concomitant Medications: An Interrupted Time Series
Diabetes, obesity & metabolism · 2026 Oct 25 · Roland N, Sonne H, Mose K et al.

Read at pubmed.ncbi.nlm.nih.gov

Source URL https://pubmed.ncbi.nlm.nih.gov/42928048/